60 Degrees shares surge 10.76% intraday after detecting Babesia infection in 24% of chronic fatigue patients, bolstering B-Free Study for ARAKODA.

60 Degrees Pharmaceuticals surged 10.76% intraday after announcing that 24% of patients in a study had Babesia infection, reinforcing its B-Free chronic babesiosis clinical trial for tafenoquine. The results support the company’s hypothesis linking Babesia to prolonged chronic fatigue and validate its expansion of Arakoda’s commercial use for babesiosis, a disease with no FDA-approved therapy. CEO Geoffrey Dow emphasized the study’s alignment with the company’s mission and highlighted ongoing trials, including a third study planned for near-term initiation. The news directly underscores the therapeutic potential of tafenoquine, which holds Orphan Drug status and patent exclusivity through 2035, positioning 60 Degrees to address an underserved market. The Bloomberg TV interview with the CEO further amplified visibility but was secondary to the clinical data as the primary catalyst for the intraday rally.